AKBA

Akebia Therapeutics (AKBA)

About Akebia Therapeutics (AKBA)

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Details

Daily high

$1.31

Daily low

$1.27

Price at open

$1.28

52 Week High

$2.48

52 Week Low

$0.78

Market cap

269.2M

Dividend yield

0.00%

Volume

829,151

Avg. volume

1.3M

P/E ratio

-6.32

Akebia Therapeutics News